ALLR Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (20 mai 2024 @ 22:00):

Stats
Dagens volum	4.36M
Gjennomsnittsvolum	3.34M
Markedsverdi	11.05M
EPS	$0 ( 2024-05-09 )
Neste inntjeningsdato	( $0 ) 2024-08-12
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0.00100 (0.16%)

Insider Trading

Date	Person	Action	Amount	type
2023-08-01	Benjamin Laura	Buy	0
2023-08-01	Vazzano Joseph Walter	Buy	0
2021-12-20	Carchedi Steve	Sell	70 477	Stock Options
2021-12-20	Carchedi Steve	Sell	156 025	Stock Options
2021-12-20	Carchedi Steve	Sell	252 555	Stock Options

INSIDER POWER
0.00
Last 5 transactions
Buy: 0 \| Sell: 505 299

Volum Korrelasjon

Lang: 0.03 (neutral)

Kort: 0.34 (neutral)

Signal:(55.149) Neutral

Allarity Therapeutics, Korrelasjon

10 Mest positive korrelasjoner
JACK	0.978
APVO	0.974
LULU	0.971
EZGO	0.963
CMTL	0.961
VEEE	0.96
HAIN	0.96
SIRI	0.957
OSUR	0.957
SRNE	0.954

10 Mest negative korrelasjoner
IVCB	-0.982
BCSA	-0.966
NKTR	-0.961
PAYS	-0.958
GDST	-0.958
SWAV	-0.958
KEQU	-0.953
NSYS	-0.951
LABP	-0.951
ENTX	-0.946

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Allarity Therapeutics, Korrelasjon - Valuta/Råvare

-0.75
( moderate negative )

-0.68
( moderate negative )

0.00
( neutral )

-0.53
( weak negative )

Allarity Therapeutics, Økonomi

Annual	2023
Omsetning:	$0
Bruttogevinst:	$-37 000.00 (0.00 %)
EPS:	$-5.98

FY	2023
Omsetning:	$0
Bruttogevinst:	$-37 000.00 (0.00 %)
EPS:	$-5.98

FY	2022
Omsetning:	$0
Bruttogevinst:	$-120 000 (0.00 %)
EPS:	$-2 359.71

FY	2021
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-0.630

Financial Reports:

No articles found.

Allarity Therapeutics, Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Allarity Therapeutics,

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.